COVID-19: -

Our Commitment to Client Service & Investor Communications

Summary: The Deepbridge Life Sciences EIS is a discretionary portfolio service that will invest into a portfolio of up to 10 underlying companies, focusing on start-up or early-stage life science companies.

Why Invest


Strategy: Well defined investment process to invest directly in new companies in selected technology areas.


Concentration: Portfolio may be up to 10 investments, although smaller investors may get greater concentration.


The Investment Adviser


Team: The Deepbridge team is very experienced in the relevant areas, and its Committees have very strong outside members.


Newer product area: Although Deepbridge has been investing in EIS since 2013, dedicated Life Science products are a relatively new area.


Nuts & Bolts

  • Investing: Deployments take place on a monthly basis, so new money will usually be invested within that period.
  • Diversification: Portfolio of between three and 10 companies.
  • Valuation: Unprofitable companies will be held at cost or at the last relevant transaction. Profitable companies use a discounted average multiple from relevant companies.


Specific Issues

  • Fees: Only the performance fee is not charged directly to the company.
  • Performance fee: Performance fee of 20% on gross returns over £1.20 on a per company basis.



  • Risk mitigation: Deepbridge aims to mitigate risk by active ongoing support of the company and choosing conservative business plans. Most of the companies will be introduced by partners, who will also be bringing support.
  • Target return: The target return for the fund is £1.70 for each gross £1 invested over three to five years. Individual companies tend to have much higher targets, reflecting that success in a company will give an excellent return, but there is a real risk of loss in any project.
Download the full report

Request a meeting

If you'd like to be introduced to the team at Deepbridge Capital (Funds), get in touch.

Request a meeting